EA201591286A1 - Количественная оценка эффективности кэп матричной рнк - Google Patents

Количественная оценка эффективности кэп матричной рнк

Info

Publication number
EA201591286A1
EA201591286A1 EA201591286A EA201591286A EA201591286A1 EA 201591286 A1 EA201591286 A1 EA 201591286A1 EA 201591286 A EA201591286 A EA 201591286A EA 201591286 A EA201591286 A EA 201591286A EA 201591286 A1 EA201591286 A1 EA 201591286A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mrna
efficiency
cep
capped
quantitative estimation
Prior art date
Application number
EA201591286A
Other languages
English (en)
Inventor
Майкл Хартлейн
Франк Дероза
Ануша Диаз
Original Assignee
Шир Хьюман Дженетик Терапис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шир Хьюман Дженетик Терапис, Инк. filed Critical Шир Хьюман Дженетик Терапис, Инк.
Publication of EA201591286A1 publication Critical patent/EA201591286A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Настоящее изобретение предоставляет, помимо прочего, способы количественной оценки эффективности кэпирования мРНК, в особенности мРНК, синтезированной in vitro. В некоторых вариантах осуществления способы согласно настоящему изобретению включают предоставление образца мРНК, содержащего кэпированную и некэпированную мРНК, предоставление кэп-специфического связывающего вещества в условиях, которые позволяют образовать комплекс между кэп-специфическим связывающим веществом и кэпированной мРНК, и количественное определение количества комплекса в сравнении с контролем с подсчетом эффективности кэпирования мРНК.
EA201591286A 2013-03-14 2014-03-14 Количественная оценка эффективности кэп матричной рнк EA201591286A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784253P 2013-03-14 2013-03-14
PCT/US2014/027602 WO2014152673A1 (en) 2013-03-14 2014-03-14 Quantitative assessment for cap efficiency of messenger rna

Publications (1)

Publication Number Publication Date
EA201591286A1 true EA201591286A1 (ru) 2016-02-29

Family

ID=50625146

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591286A EA201591286A1 (ru) 2013-03-14 2014-03-14 Количественная оценка эффективности кэп матричной рнк

Country Status (13)

Country Link
US (3) US10626439B2 (ru)
EP (2) EP3495505A1 (ru)
JP (1) JP2016515216A (ru)
CN (1) CN105209633A (ru)
AU (1) AU2014239264A1 (ru)
BR (1) BR112015022141A2 (ru)
CA (1) CA2903488A1 (ru)
DK (1) DK2971098T3 (ru)
EA (1) EA201591286A1 (ru)
ES (1) ES2708562T3 (ru)
MX (1) MX2015011945A (ru)
TR (1) TR201901396T4 (ru)
WO (1) WO2014152673A1 (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
CA3107288A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
AU2012267578B2 (en) 2011-06-08 2017-04-20 Translate Bio, Inc. Cleavable lipids
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
AU2014239250A1 (en) 2013-03-14 2015-08-27 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger RNA
EA037922B1 (ru) 2013-03-14 2021-06-07 Шир Хьюман Дженетик Терапис, Инк. мРНК CFTR И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ МУКОВИСЦИДОЗА У МЛЕКОПИТАЮЩЕГО
EP2970955B1 (en) 2013-03-14 2018-11-14 Translate Bio, Inc. Methods for purification of messenger rna
MX2015011945A (es) 2013-03-14 2015-12-01 Shire Human Genetic Therapies Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
EP4276176A3 (en) 2013-10-22 2024-01-10 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
EA034103B1 (ru) 2013-10-22 2019-12-27 Транслейт Био, Инк. СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
JP6571679B2 (ja) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
EP3169335B8 (en) 2014-07-16 2019-10-09 ModernaTX, Inc. Circular polynucleotides
SE539096C2 (en) * 2015-03-18 2017-04-04 C Conjunction Ab A method, system and software application for providing context based commercial information
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
CN116590285A (zh) 2015-09-21 2023-08-15 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
CN108473969B (zh) 2015-10-14 2022-09-13 川斯勒佰尔公司 用于增强生产的rna相关酶的修饰
EP3362460A1 (en) * 2015-10-16 2018-08-22 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
WO2017066797A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
EP3656872A1 (en) * 2015-12-09 2020-05-27 Novartis AG Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
GB201615233D0 (en) * 2016-09-08 2016-10-26 Bbi Solutions Oem Ltd Solid Phase Conjugate
HUE059025T2 (hu) 2017-02-27 2022-10-28 Translate Bio Inc Módszerek a hírvívõ RNS tisztítására
ES2925083T3 (es) 2017-02-27 2022-10-13 Translate Bio Inc Métodos de purificación de ARN mensajero
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
AU2018268859A1 (en) 2017-05-16 2019-12-12 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
CN111032863A (zh) * 2017-06-30 2020-04-17 科德克希思公司 T7 rna聚合酶变体
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
WO2020072914A1 (en) 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
AU2019364545A1 (en) * 2018-10-26 2021-04-29 Illumina, Inc. Modulating polymer beads for DNA processing
WO2020097509A1 (en) 2018-11-08 2020-05-14 Translate Bio, Inc. Methods and compositions for messenger rna purification
CA3122645A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
CA3139679A1 (en) 2019-05-15 2020-11-19 Translate Bio, Inc. Methods for purification of messenger rna
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
MX2022001870A (es) 2019-08-14 2022-05-30 Curevac Ag Combinaciones y composiciones de arn con propiedades inmunoestimuladoras disminuidas.
CN112626177A (zh) * 2019-10-09 2021-04-09 华中科技大学 一种快速定量检测rna加帽效率的方法
KR20220144416A (ko) 2020-02-04 2022-10-26 큐어백 아게 코로나바이러스 백신
IL298084A (en) 2020-05-29 2023-01-01 CureVac SE Nucleic acid-based combination vaccines
CA3187138A1 (en) * 2020-06-26 2021-12-30 Carisma Therapeutics Inc. Mrna transfection of immune cells
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
CN113337560A (zh) * 2020-08-20 2021-09-03 深圳市瑞吉生物科技有限公司 一种Cap2结构5`帽子类似物及其制备方法和应用
WO2022043551A2 (en) 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US20240102065A1 (en) 2021-01-27 2024-03-28 CureVac SE Method of reducing the immunostimulatory properties of in vitro transcribed rna
JP2024511206A (ja) 2021-03-26 2024-03-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
EP4351777A1 (en) * 2021-06-07 2024-04-17 The University of Massachusetts Apparatus and method for continuous production of rna
IL309502A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine
CN115260264B (zh) * 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
CN117730157A (zh) * 2022-04-15 2024-03-19 萨默费尼根有限公司 用于定量监测mRNA加帽效率的方法
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
US20240156949A1 (en) 2022-10-28 2024-05-16 Glaxosmithkline Biologicals Sa Nucleic Acid Based Vaccine
CN116426610B (zh) * 2023-06-08 2024-01-05 启辰生生物科技(珠海)有限公司 一种LC-MS法准确定量mRNA加帽效率的方法
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
DE4140463A1 (de) 1991-12-09 1993-06-17 Boehringer Mannheim Gmbh 2'-desoxy-isoguanosin, dessen isostere analoge sowie anwendung derselben
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
ATE232880T1 (de) 1996-11-18 2003-03-15 Takeshi Imanishi Neue nucleotidanaloga
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
ES2242291T5 (es) 1997-09-12 2016-03-11 Exiqon A/S Análogos de nucleósidos bicíclicos y tricíclicos, nucleótidos y oligonucleótidos
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
EP1214331B1 (en) 1999-08-30 2006-10-11 Roche Diagnostics GmbH 2-azapurine compounds and their use
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
US20020197622A1 (en) 2001-01-31 2002-12-26 Mcdevitt John T. Method and apparatus for the confinement of materials in a micromachined chemical sensor array
WO2004020575A2 (en) * 2002-06-24 2004-03-11 Exiqon A/S Methods and systems for detection and isolation of a nucleotide sequence
US20070281336A1 (en) 2006-04-14 2007-12-06 Epicentre Technologies Kits and methods for generating 5' capped RNA
CA2659301A1 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
US20100035249A1 (en) 2008-08-05 2010-02-11 Kabushiki Kaisha Dnaform Rna sequencing and analysis using solid support
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
MX2015011945A (es) 2013-03-14 2015-12-01 Shire Human Genetic Therapies Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
AU2014239250A1 (en) 2013-03-14 2015-08-27 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger RNA
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
WO2019207060A1 (en) 2018-04-25 2019-10-31 Ethris Gmbh Lipid-based formulations for the delivery of rna

Also Published As

Publication number Publication date
BR112015022141A2 (pt) 2017-08-29
EP3495505A1 (en) 2019-06-12
WO2014152673A1 (en) 2014-09-25
ES2708562T3 (es) 2019-04-10
US11920182B2 (en) 2024-03-05
CN105209633A (zh) 2015-12-30
MX2015011945A (es) 2015-12-01
US20160002705A1 (en) 2016-01-07
US10626439B2 (en) 2020-04-21
US20200318156A1 (en) 2020-10-08
US11104934B2 (en) 2021-08-31
US20210371900A1 (en) 2021-12-02
DK2971098T3 (en) 2019-02-18
CA2903488A1 (en) 2014-09-25
EP2971098B1 (en) 2018-11-21
AU2014239264A1 (en) 2015-08-27
TR201901396T4 (tr) 2019-02-21
JP2016515216A (ja) 2016-05-26
EP2971098A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
EA201591286A1 (ru) Количественная оценка эффективности кэп матричной рнк
EA201591283A1 (ru) Количественная оценка эффективности кэп матричной рнк
HK1217971A1 (zh) 用於核酸分析的方法、組合物和試劑盒
EA201492101A1 (ru) Антитела против fcrn
PH12015502039B1 (en) Anti-lag-3 binding proteins
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
EA201400709A1 (ru) Молекула биспецифического антитела
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
BR112014001026A2 (pt) codificação de matriz de amostra de baixo atrasdo
HK1222180A1 (zh) 用於生物樣品中的具有提高的性能的 測定
EA201592223A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA SERPINAl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
PH12015501687A1 (en) Novel binding proteins from pcsk9
CL2015000752A1 (es) Nuevos ligandos de rig-i y metodos para producirlos
EP3014647A4 (en) MASS SPECTROMETRY ANALYSIS OF MICROORGANISMS IN SAMPLES
GB201205769D0 (en) Methods for preparing samples for nucleic acid amplification
NZ704719A (en) Cd133 aptamers for detection of cancer stem cells
PT3084432T (pt) Quantificação de glucocorticoides em escamas de peixe, espinhas, raios de barbatana ou otólitos como biomarcadores para stresse crónico
PH12016500753A1 (en) Antibodies specific to fcrn
WO2012102527A3 (ko) 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
DK201300530A (en) Vaccine relating to Pancreas disease in fish
GB2495884A (en) A method of increasing the effect of an activated-potentiated form of an antibody
MX2017011198A (es) Biomarcadores para preeclampsia.
MX368486B (es) Plantas cucurbitaceas androceas, metodos de obtencion y usos de dichas plantas cucurbitaceas.
BR112013032223A2 (pt) molécula de ácido nucleico isolada, e, composição